openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Fortrea Holdings Inc. (NASDAQ: FTRE) over potential Wrongdoing

An investigation on behalf of current long term investors in Fortrea Holdings Inc. (NASDAQ: FTRE) shares.

An investigation on behalf of current long term investors in Fortrea Holdings Inc. (NASDAQ: FTRE) shares.

An investigation was announced for current long-term investors in shares of Fortrea Holdings Inc. (NASDAQ: FTRE) concerning potential breaches of fiduciary duties by certain directors of Fortrea Holdings Inc.

Investors who are current long term investors in Fortrea Holdings Inc. (NASDAQ: FTRE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: FTRE stocks follows a lawsuit filed against Fortrea Holdings Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: FTRE stocks, concerns whether certain Fortrea Holdings Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings, that Fortrea overstated the cost savings it would likely achieve by exiting the TSAs, that as a result, the Company's previously announced EBITDA targets for 2025 were inflated, that accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Fortrea Holdings Inc. (NASDAQ: FTRE) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Fortrea Holdings Inc. (NASDAQ: FTRE) over potential Wrongdoing here

News-ID: 4167114 • Views:

More Releases from Shareholders Foundation, Inc.

Investigation announced for Long-Term Investors in shares of Red Cat Holdings, Inc. (NASDAQ: RCAT)
Investigation announced for Long-Term Investors in shares of Red Cat Holdings, I …
An investigation was announced for current long-term investors in shares of Red Cat Holdings, Inc. (NASDAQ: RCAT) concerning potential breaches of fiduciary duties by certain directors of Red Cat Holdings, Inc. Investors who are current long term investors in Red Cat Holdings, Inc. (NASDAQ: RCAT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long
Lawsuit was filed for Investors who lost money with shares in CTO Realty Growth, Inc. (NYSE: CTO)
Lawsuit was filed for Investors who lost money with shares in CTO Realty Growth, …
An investor, who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO), filed a lawsuit over alleged violations of Federal Securities Laws by CTO Realty Growth, Inc. in connection with certain allegedly false and misleading statements made between February 18, 2021 and June 24, 2025. Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and for certain investors are short and strict deadlines running. Deadline: October
Investigation announced for Long-Term Investors in shares of Organon & Co. (NYSE: OGN) concerning potential Wrongdoing
Investigation announced for Long-Term Investors in shares of Organon & Co. (NYSE …
An investigation was announced for current long-term investors in shares of Organon & Co. (NYSE: OGN) concerning potential breaches of fiduciary duties by certain directors of Organon & Co. Investors who are current long term investors in Organon & Co. (NYSE: OGN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors
Lawsuit filed for Investors who lost money with shares of Charter Communications, Inc. (NASDAQ: CHTR)
Lawsuit filed for Investors who lost money with shares of Charter Communications …
An investor, who purchased shares of Charter Communications, Inc. (NASDAQ: CHTR), filed a lawsuit over alleged violations of Federal Securities Laws by Charter Communications, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Charter Communications, Inc. (NASDAQ: CHTR) have certain options and for certain investors are short and strict deadlines running. Deadline: October 14, 2025. NASDAQ: CHTR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Fortrea

Investors who lost money with shares of Fortrea Holdings Inc. (NASDAQ: FTRE) sho …
An investor, who purchased shares of Fortrea Holdings Inc. (NASDAQ: FTRE), filed a lawsuit over alleged violations of Federal Securities Laws by Fortrea Holdings Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fortrea Holdings Inc. (NASDAQ: FTRE) have certain options and for certain investors are short and strict deadlines running. Deadline: August 1, 2025. NASDAQ: FTRE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Sickle Cell Disease Market Expected to Experience Major Growth by 2034, Accordin …
The Key Sickle Cell Disease Companies in the marke include - Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others. DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Sickle Cell Disease, historical
Virtual Clinical Trials Market Future Business Scope Analysis Report, Marketing …
The Virtual Clinical Trials Market research report not only assists newly entered businesses but also assists businesses of all levels, shapes, scope, experience levels and sizes. This report also provides a way for key organizations to further expansion and business growth. Potential areas are spotted in this market research report for the business expansion. This research report reveals important insights into the market scenario to enable key players to take
Sickle Cell Disease Market Growth Projections 2024-2034: DelveInsight Analysis | …
DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom. To Know in detail about the Sickle Cell Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sickle Cell Disease Market Forecast https://www.delveinsight.com/sample-request/sickle-cell-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Insights into the Pediatric Drug Development Services Market 2025: Healthy CAGR …
The latest research study released by Worldwide Market Reports on "Pediatric Drug Development Services Market 2025" holds tons of experience in offering comprehensive and accurate analysis of global as well as regional markets. The analysts and researchers authoring the report have provided a deeper competitive analysis of the Pediatric Drug Development Services market along with exhaustive company profiling of leading market players. This research study of the Pediatric Drug Development
Sickle Cell Disease Market to Show Remarkable Growth Trends from 2024 to 2034, D …
The Key Sickle Cell Disease Companies in the market include - Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others. DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Sickle Cell Disease, historical